Skip to main content
Vito Quaranta on Muck Rack

Vito Quaranta

As seen in: Nature, PLOS Biology, MDPI, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vito

Contact Vito, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Small cell lung cancer induces synaptic scaling to alter neuronal excitability - Communications Biology

|
By Lisa M. Monteggia, Vito Quaranta, Amanda Linkous
| Nature Verified
Abstract Tumor cell plasticity in novel microenvironments is central to the integration and subsequent growth of metastatic cells. However, the functional consequences of tumor cell integration with central neurons remains understudied. Here, we address this question using small cell lung cancer (SCLC), which has an extraordinary propensity to metastasize to the brain in humans.
Open in Who Shared Issue with article?

Purinergic Ca2+ Signaling as a Novel Mechanism of Drug Tolerance in BRAF-Mutant Melanoma

|
By Philip E Stauffer, Jordon Brinkley, David Jacobson, Vito Quaranta
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared View Duplicates (153) Issue with article?

Purinergic Ca2+ signaling as a novel mechanism of drug tolerance in BRAF mutant melanoma

|
By Philip E Stauffer, Jordon Brinkley, David Jacobson, Vito Quaranta
| BioRxiv
Abstract Drug tolerance is a major cause of relapse after cancer treatment. In spite of intensive efforts, its molecular basis remains poorly understood, hampering actionable intervention. We report a previously unrecognized signaling mechanism supporting drug tolerance in BRAF-mutant melanoma treated with BRAF inhibitors that could be of general relevance to other cancers.
Open in Who Shared Issue with article?
See all 5 articles